← Back to Search

Mobile Chatbot Support for Cancer Survivor Care

N/A
Recruiting
Research Sponsored by Abramson Cancer Center at Penn Medicine
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights

Study Summary

This trial will identify strategies to help cancer survivors reengage with healthcare and evaluate the effect of a new conversational agent, "Penny", to help them schedule appointments and other medical needs.

Who is the study for?
This trial is for adult survivors of childhood and young adult cancers (diagnosed from birth to age 39) who haven't had follow-up care in over 3 years. Participants must own a mobile device capable of SMS texts, speak English, consent to the study, and have their oncology team's approval.Check my eligibility
What is being tested?
The study tests 'Penny,' a chatbot designed to help cancer survivors reengage with healthcare by aiding in scheduling appointments and necessary medical procedures. It will be compared against the standard follow-up care practices.See study design
What are the potential side effects?
Since 'Penny' is a digital conversational agent used for communication purposes rather than a medication or therapy, there are no direct physical side effects associated with its use.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of patients who agree to use Penny and patient engagement overtime in those patients randomized to the Penny arm
To evaluate the utilization of a chatbot (Penny) to increase receipt of evidence-based survivorship care in YA survivors of pediatric and YA cancers

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Penny text-messaging programExperimental Treatment1 Intervention
Group II: Usual CareActive Control1 Intervention

Find a Location

Who is running the clinical trial?

Abramson Cancer Center at Penn MedicineLead Sponsor
387 Previous Clinical Trials
145,594 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are investigators presently recruiting participants for this experiment?

"This clinical trial, which was initially posted on September 11th 2023 is currently recruiting patients. The data has been modified as of the 19th of the same month."

Answered by AI

How extensive is the pool of participants engaging in this experiment?

"Affirmative. Clinicaltrials.gov records show that this clinical trial, first posted on September 11th 2023, is still actively recruiting participants. They are in need of 50 volunteers from a single location."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Staying Healthy With Follow-up Care: A Mobile Chatbot Feasibility Study for AYA Cancer Survivors
2023. "Staying Healthy With Follow-up Care: A Mobile Chatbot Feasibility Study for AYA Cancer Survivors". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05863702.
~32 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top